InsiderPulse| Trade Date | Filed | Owner | Role | Type | Shares | Price | Value | Owned After | ||
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-05-01 | 2026-05-05 | Warmuth Markus | Director & President & CEO | Sale | 5,467 | $18.92 | $103K | 600.0K | View ↗ | |
| 2026-04-14 | 2026-04-15 | Warmuth Markus | Director & President & CEO | Sale | 8,000 | $17.64 | $141K | 605.5K | View ↗ | |
| 2026-04-09 | 2026-04-10 | Nickson Philip | Chief Business & Legal Officer | Sale | 5,845 | $17.69 | $103K | 55.0K | View ↗ | |
| 2026-03-04 | 2026-03-05 | Dunn Edmund | Principal Accounting Officer | Sale | 139 | $17.96 | $2K | 22.6K | View ↗ | |
| 2026-03-02 | 2026-03-04 | Warmuth Markus | Director & President & CEO | Sale | 5,466 | $17.92 | $98K | 613.5K | View ↗ |
No annual data found.
Monte Rosa Trial Progress And Valuation Gap Draw Investor Attention
Monte Rosa Therapeutics (GLUE) Reports Q1 Loss, Misses Revenue Estimates
Monte Rosa Therapeutics Announces First Quarter 2026 Financial Results and Business Updates
Myriad Genetics (MYGN) Reports Q1 Loss, Misses Revenue Estimates